Microbial determinants of effective donors in faecal microbiota transplantation for UC. Issue 1 (25th July 2022)

• Record Type: Journal Article
• Authors: Haifer, Craig; Luu, Laurence Don Wai; Paramsothy, Sudarshan; Borody, Thomas J; Leong, Rupert W; Kaakoush, Nadeem O
• Is Part Of: Gut. Volume 72:Issue 1(2023)
• Page Start: 90
• Page End: 100
• Publication Date: 2022-07-25
• Subjects: ULCERATIVE COLITIS -- COLONIC MICROFLORA -- IBD; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2022-327742
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Faecal microbiota transplantation (FMT) has variable efficacy in treating UC. Recently, oral lyophilised FMT was found to induce remission in patients with UC, with one donor having 100% efficacy compared with a second donor (36% efficacy). We characterised differences in the gut microbiota of these two donors with the aim of improving FMT donor selection. Design: Faecal samples from the two donors were collected over a period of 44 (donor 1) or 70 (donor 2) weeks. The microbiome and metabolome were profiled using shotgun metagenomics and untargeted metabolomics Results: Gut microbiome long-term stability was highly evident in the effective donor. Donor microbiota species evenness was a robust feature associated with clinical efficacy across two clinical trials of FMT in UC, leading to increased donor species engraftment in patients. Alpha diversity and beta diversity of donor gut microbiotas significantly differed. 90 bacterial species and one archaeon were differentially abundant between donors, 44 of which were >0.1% in relative abundance. 17/44 species were enriched in the effective donor, 11 of which (64.7%) were assembled into high-quality genomes that were prevalent (≥75% samples) in that donor, and six showed evidence of engraftment in patients. Taxonomic differences between donors translated to substantial microbial functional differences that were validated using metabolomics. Conclusion: Donor microbiota stability and species evenness were identified as novel metrics that were associated with therapeutic efficacy in UC, beyond individual microbial species or metabolites. These metrics may represent community resilience that translates to better engraftment in the host. Trial registration number: ACTRN12619000611123.